| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Susan Wang last filed a Form 4 in November 2015, as Director at NKTR. The filings on record cover 3 companies. Susan Wang's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 20,000 shares of NKTR. The NKTR filings lean toward selling, a net 115,000 shares.
Susan Wang has 5 Form 4 filings on record from February 2015 to November 2015, across 3 companies: Director at Nektar Therapeutics (NKTR), 2015; Director at Veeco Instruments (VECO), 2015; Director at Cirrus Logic (CRUS), 2015.
The 20 reported transactions were 9 open-market sales, 8 option exercises, 2 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $2.9M.
The largest open-market sale was 85,000 shares of NKTR at an average $15.02 on November 20, 2015, about $1.3M.
Shares as reported in the last Form 4 for each company; the most recent is from November 2015. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.